MENU
APLS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Apellis Pharmaceuticals (APLS) Earnings Date & Reports

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more

A.I. Advisor
published Earnings

APLS is expected to report earnings to fall 122.23% to -37 cents per share on March 04

Apellis Pharmaceuticals APLS Stock Earnings Reports
Q4'25
Est.
$-0.37
Q3'25
Beat
by $0.12
Q2'25
Beat
by $0.15
Q1'25
Missed
by $0.40
Q4'24
Beat
by $0.08
The last earnings report on October 30 showed earnings per share of $1.67, beating the estimate of $1.55. With 3.07M shares outstanding, the current market capitalization sits at 2.51B.
View a ticker or compare two or three
APLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. APLS showed earnings on October 30, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
706
Web
https://www.apellis.com